• Aim: To compare the effectiveness between multiple intravitreal injections of ganciclovir alone and combined with foscarnet as initial treatment for patients with newlyonset cytomegalovirus retinitis (CmVR).
INTRODUCTION
C ytomegalovirus retinitis (CMVR) is one of the major causes of visual blindness in patients with immunocompromised disorders such as acquired immunodeficiency syndrome (AIDS) and hematopoietic stem cell transplantation [1] [2] [3] . Recent studies showed that poor visual outcome with visual acuity less than 20/200 will be found in 13% to 60% of affected eyes [4] [5] [6] [7] . Intravitreal injection of anti-viral agents against cytomegalovirus (CMV) has been widely used as a crucial treatment for CMVR [8] [9] . As compared to systemic use, administration through intravitreal injections results in higher retinal tissue concentrations but lower systemic exposure [10] . Ganciclovir has been used to treat human CMV infection since 1983. However, ganciclovir-resistant CMV infections have been found in some patients with end-organ CMV diseases [11] , and the vast majority of infections caused by drug-resistant CMV have been found in patients with AIDS [12] [13] . Severe ocular complications such as retinal detachment and irreversible visual loss more commonly happens if the infection cannot be controlled promptly or occurs recurrently. In such cases, foscarnet is usually used to treat the ganciclovir-resistant CMV infections [14] [15] [16] . Both ganciclovir or foscarnet have been proven to be effective in treating CMVR through intravitreal administration [17] [18] [19] .
Moreover, combined therapy by these two drugs has been shown to be effective in treating recurrent CMVR or when the infection is clinically resistant to either drug alone [20] [21] .
Theoretically, using a combination of these two drugs as initial therapy might enhance the anti-viral effect and reduce the nonresponse rate of treatments, followed by a better outcome. However, few studies have used the combination therapy as initial treatment, or even compared the effectiveness and safety between monotherapy and combination therapy as initial treatment for CMVR. We therefore performed a comparative study to evaluate the difference in laboratory and clinical outcomes of CMVR by following these two strategies. [19] . Patients' best corrected visual acuity, viral DNA load of CMV and detail clinical findings at baseline and 1wk after each injection were collected and reviewed. Real-time polymerase chain reaction (PCR) was applied to detect the DNA load of CMV in patient's aqueous humor. CMV real-time PCR kit mix contains reagents and enzymes for the specific amplification of immediate early gene region of the human CMV-DNA. A standard curve was obtained from the quantitation standard CMV-DNA positive controls provided by the manufacturer. Statistical analysis was done using a commercially available statistical software package (SPSS for Windows, version 21.0; IBM-SPSS, Chicago, IL, USA). The normality of data was tested by the Shapiro-Wilk test. Visual acuity was converted into the logarithm of the minimum angle of resolution (logMAR) for statistical calculation [24] . By using boxplots, the mean virus loads of CMV, visual acuity and intraocular pressures were compared against the times of injection, and the trend of which changed with time were judged from it.
SUBJECTS AND METHODS
Chi-square and t-test were used for univariate nonparametric analyses. All p-values were 2-sided and were considered statistically significant if <0.05. RESULTS A total of 58 eyes with CMVR in 37 patients fulfilled the inclusion criteria and did not meet any exclusion criteria within the study period. Of these patients, 2 had AIDS, 34 received hematopoietic stem cell transplantation and 1 received thymectomy. Twenty-four patients (35 eyes) with a mean age of 37.2y underwent 4 weekly injections of ganciclovir and were categorized in the IVG group. On the other hand, 23 eyes in 13 patients with a mean age of 41.1y underwent 4 weekly injections of ganciclovir combined with foscarnet and were categorized in the IVG+F group (Table 1) . The mean duration from onset of visual symptoms to treatment was 2.6±1.2wk. There is no difference between patients' characteristics and ocular conditions among these two groups (Tables 1, 2 ). The CMV-DNA copies in affected eyes decreased remarkably with the time of injections in both groups. In the IVG group, the mean value of CMV-DNA copies decreased from 38.3×10 4 copies/mL at baseline to 2.2×10 4 copies/mL at the 4 th injection. Whereas in the IVG+F group, the mean value of CMV-DNA copies decreased from 76.9×10 4 copies/mL at baseline to 11.3×10 4 copies/mL at the 4 th injection. Although there were significant reductions of DNA load in both IVG and IVG+F groups (p=0.02 and <0.01, respectively), no statistically significant difference in the amount of reduction between each group were found (p=0.12; Table 2 , Figure 1 ). No significant worsening or change of patients' visual acuity from baseline to the 4 th injection was found in both two groups (p=0.37 and 0.71; Figures 2, 3) . Among all affected eyes in the IVG group, visual acuity remained the same in 16.7% of eyes, improved in 66.7% of eyes and decreased in 16.7% of eyes.
On the other hand, the vision remained the same in 17.4% of eyes in the IVG+F group, 52.2% of eyes had improved vision, and 30.4% of eyes had worse vision. No significant differences were found in change of visual acuity and intraocular pressures between the two groups (p=0.21 and 0.17, respectively). 
DISCUSSION
CMVR is an important sight-threatening disease in immunocompromised patients. Previous studies have clearly showed that intravitreal therapy offers a significant advantage over systemic therapy in the treatment of CMVR by substantially reducing the risk of CMVR-complicated retinal detachment [22] . Ganciclovir is a nucleoside analogue which can be used against viruses of the herpetic family, including CMV. CMV phosphotransferase (UL97) gene and DNA polymerase (UL54) gene play a crucial rule in its anti-viral mechanism [10] .
CMVs that have mutations in UL97 and UL54 can easily resist ganciclovir. On the other hand, foscarnet is another pyrophosphate analogue which inhibits viral polymerases but does not depend on any phosphorylation or activation secondary to viral infection [16] [17] 23] .
Intravitreal injection of ganciclovir with a dosage of 2.0 to 5.0 mg is effective and has been approved for treating CMVR [24] . Pharmacokinetic studies have demonstrated that the concentrations in vitreous after one shoot can be maintained above the ID50 (0.25 to 1.22 mg/mL) for up to 7d. Based on the clinical response and disease course of CMVR, weekly injections of anti-viral agents were usually required at the acute infectious stage. Monotherapy with intravitreal ganciclovir or foscarnet is usually used when the patient first suffered from CMVR, and a combination of these two drugs is used when the infection resists either one of the drugs or recurs during treatment [20] [21] . However, the prolonging or recurrence of disease course may lead to severe ocular complications such as macular involvement or retinal detachment. The viral DNA load of CMV and visual acuity are two important indicators to evaluate the virological and clinical treatment effect in CMVR. In this study, we recorded the DNA load in aqueous humor and patients' visual acuity each time before and after the intravitreal injection. The results indicated that the CMV-DNA copies reduced significantly in both groups. However, the reduction of mean CMV-DNA copies after 4 weekly injections for patients with CMVR were not significantly different whether we used monotherapy or combination therapy as initial treatments.
On the other hand, the average duration from onset to treatments was 2.6wk in our patients. The visual acuity in 17% of patients' eyes remained the same after 4 weekly injections and improved in 52.2% to 66.7% of eyes. Although the mean visual acuity did not change significantly in both groups, our results suggested that treating with intravitreal anti-viral agents promptly was indeed effective in preserving vision in affected eyes. The changes of visual acuities or intraocular pressures between both groups were not statistically significant. This implies that monotherapy with ganciclovir might be enough and sufficient for control of CMVR initially. There were two limitations in this study. First, the study was designed as a retrospective study, rather than perspective. The possibility of clinical selection bias cannot be completely excluded. However, not only patients' general characteristics, but also baseline viral DNA load and visual acuity were similar in both groups (p>0.05). We assumed that there was no obvious selection bias that would affect the findings in this study. Second, since the duration of follow-up period in this study was short, the long-term recurrent rate of CMVR or other outcome cannot be compared. However, due to the difficulty of judgement of complete cure of CMVR in a short period of time, it might be better to compare the results of patients between each group after 4 consensus injections. In summary, weekly intravitreal injections of both ganciclovir monotherapy and combination of gancivlovir with foscarnet can effectively reduce intraocular viral load of CMV. The reduction of mean CMV-DNA copies and the change of visual acuity after 4 continuous injections were not statistically different between monotherapy or combine therapy. To our knowledge, this is the first study to compare the effect of intravitreal ganciclovir monotherapy and that combined with foscarnet as initial treatment for newly developed CMVR.
